Chemed (CHE) Expected to Release Quarterly Earnings on Tuesday

Chemed (NYSE:CHE) is expected to announce its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect Chemed to post earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. During the same period last year, the firm posted $4.27 earnings per share. Chemed’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts expect Chemed to post $23.55 EPS for the current fiscal year and $25.17 EPS for the next fiscal year.

Chemed Trading Down 1.4%

Shares of Chemed stock opened at $512.72 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. Chemed has a 1 year low of $365.20 and a 1 year high of $557.00. The firm has a market cap of $6.70 billion, a PE ratio of 25.75, a PEG ratio of 2.06 and a beta of 0.51. The company has a 50 day simple moving average of $514.99 and a two-hundred day simple moving average of $475.86.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, August 17th. This is a positive change from Chemed’s previous quarterly dividend of $0.60. Chemed’s payout ratio is currently 14.06%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CHE. UBS Group assumed coverage on shares of Chemed in a research report on Friday, September 25th. They set a “buy” rating and a $650.00 price objective on the stock. Royal Bank Of Canada upped their target price on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Oppenheimer increased their target price on Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Wall Street Zen raised Chemed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Finally, Bank of America restated a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Chemed presently has a consensus rating of “Hold” and a consensus price target of $554.60.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the transaction, the chief executive officer directly owned 66,418 shares in the company, valued at $34,102,322.10. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick P. Grace sold 190 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director owned 3,533 shares in the company, valued at $1,879,556. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 9,190 shares of company stock worth $4,833,160 in the last quarter. 3.33% of the stock is owned by insiders.

Chemed Company Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.